Baxter International Inc. (BAX) Receives $65.42 Consensus PT from Analysts

Shares of Baxter International Inc. (NYSE:BAX) have been assigned a consensus recommendation of “Buy” from the fifteen research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, six have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $65.42.

BAX has been the subject of several recent analyst reports. Stifel Nicolaus raised their price target on Baxter International from $58.00 to $61.00 and gave the stock a “hold” rating in a report on Wednesday, May 31st. Barclays PLC raised their price target on Baxter International from $62.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, June 14th. Cantor Fitzgerald initiated coverage on Baxter International in a report on Thursday, June 29th. They issued an “overweight” rating and a $70.00 price target for the company. Cowen and Company reissued a “market perform” rating and issued a $66.00 price target (up previously from $57.00) on shares of Baxter International in a report on Monday, July 10th. Finally, BMO Capital Markets raised Baxter International from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $55.00 to $70.00 in a report on Tuesday, July 11th. They noted that the move was a valuation call.

In related news, Director John D. Forsyth sold 9,440 shares of Baxter International stock in a transaction that occurred on Friday, August 25th. The stock was sold at an average price of $61.76, for a total transaction of $583,014.40. Following the completion of the transaction, the director now directly owns 32,444 shares in the company, valued at $2,003,741.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Thomas T. Stallkamp sold 8,920 shares of Baxter International stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $62.28, for a total value of $555,537.60. Following the transaction, the director now owns 16,263 shares of the company’s stock, valued at $1,012,859.64. The disclosure for this sale can be found here. Insiders have sold 35,050 shares of company stock valued at $2,158,587 in the last ninety days. Corporate insiders own 0.05% of the company’s stock.

A number of hedge funds have recently made changes to their positions in BAX. BlackRock Inc. raised its position in Baxter International by 1,941.1% during the first quarter. BlackRock Inc. now owns 46,937,709 shares of the medical instruments supplier’s stock valued at $2,434,190,000 after acquiring an additional 44,638,052 shares in the last quarter. Bessemer Group Inc. raised its position in Baxter International by 42,907.2% during the second quarter. Bessemer Group Inc. now owns 4,652,950 shares of the medical instruments supplier’s stock valued at $281,690,000 after acquiring an additional 4,642,131 shares in the last quarter. Renaissance Technologies LLC raised its position in Baxter International by 2,859.6% during the first quarter. Renaissance Technologies LLC now owns 1,897,115 shares of the medical instruments supplier’s stock valued at $98,384,000 after acquiring an additional 1,833,015 shares in the last quarter. Victory Capital Management Inc. raised its position in Baxter International by 438.8% during the first quarter. Victory Capital Management Inc. now owns 1,968,222 shares of the medical instruments supplier’s stock valued at $102,072,000 after acquiring an additional 1,602,894 shares in the last quarter. Finally, CI Global Investments Inc. purchased a new position in Baxter International during the first quarter valued at approximately $76,714,000. Institutional investors own 83.62% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Baxter International Inc. (BAX) Receives $65.42 Consensus PT from Analysts” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/09/19/baxter-international-inc-bax-receives-65-42-consensus-pt-from-analysts.html.

Shares of Baxter International (BAX) traded down 0.45% during trading on Friday, reaching $64.02. The company’s stock had a trading volume of 1,825,497 shares. Baxter International has a 12-month low of $43.13 and a 12-month high of $64.75. The firm’s 50-day moving average is $61.61 and its 200-day moving average is $57.88. The stock has a market capitalization of $34.88 billion, a PE ratio of 38.85 and a beta of 0.66.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Wednesday, July 26th. The medical instruments supplier reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.06. The business had revenue of $2.61 billion during the quarter, compared to the consensus estimate of $2.59 billion. Baxter International had a return on equity of 14.82% and a net margin of 8.85%. The company’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter last year, the company earned $0.46 earnings per share. Equities analysts expect that Baxter International will post $2.39 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 2nd. Investors of record on Friday, September 1st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 1.00%. The ex-dividend date is Wednesday, August 30th. Baxter International’s dividend payout ratio (DPR) is 38.79%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply